- The National Academies of Sciences, Engineering, and Medicine released a report criticizing the persistent lack of diversity among participants in clinical trials. The authors note that the underrepresentation is causing serious issues, including the inability to generalize research to the larger U.S. population and a lack of trust in the clinical research and medical establishments by those who have been historically excluded from clinical trials. They urge funders to enforce diversity targets by better tracking the diversity of trial participants, withholding funding for trials that do not meet goals, and offering tax credits or other financial incentives for those who do increase representation. (Report here; Article here)
May 18, 2022
Inequities and SDOH